Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.77
-3.83 (-1.58%)
AAPL  259.75
-1.30 (-0.50%)
AMD  223.41
+2.44 (1.11%)
BAC  51.83
-2.71 (-4.97%)
GOOG  333.19
-3.24 (-0.96%)
META  620.55
-10.54 (-1.67%)
MSFT  464.49
-6.18 (-1.31%)
NVDA  182.29
-3.52 (-1.89%)
ORCL  195.42
-6.87 (-3.40%)
TSLA  439.84
-7.36 (-1.65%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.